[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496688":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":24,"locations":23,"responsibleParty":34,"collaborators":23,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":23,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":23,"enrollmentInfo":47,"targetDuration":23,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":23,"overallStatus":56,"whyStopped":23,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":23},{"fullName":5,"class":6},"Corporacion Parc Tauli","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Omentectomy","Omentectomy during cancer gastric surgery",[12],"Other: Surgery procedure",{"label":14,"type":6,"description":15,"interventionNames":16},"Omental preservation","Preserval omentation during cancer gastric surgery",[12],[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"Surgery procedure","Omentectomy vs omental preservations during gastric surgery",[14,9],[9,14],null,[25,31],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Sandra Montmany, PhD","CONTACT","937231010","21490","smontmany@tauli.cat",{"name":32,"role":27,"phone":28,"phoneExt":29,"email":33},"Andrea Torrecilla, MD","atorrecillaportoles@gmail.com",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Sandra Montmany-Vioque","MD, PhD","100496688","omentectomy-vs-omental-preservation-in-resectable-cancer-100496688",false,"NCT05747482","Omentectomy vs Omental Preservation in Resectable Cancer","Non-inferiority Randomized Clinical Trial Comparing Omenectomy and Omental Preservation in Resectable Gastric Cancer","Inclusion Criteria:\n\n* Older than 18 years old\n* Resectable gastric cancer\n* Gastric cancer T3-4 N+\u002F- M0\n\nExclusion Criteria:\n\n* M1\n* Non surgical patients for medical status\n* Non resectable gastric cancer during surgery\n* Endoscopic resectable gastric cancer","ALL","18 Years",{"count":48,"type":49},569,"ESTIMATED","INTERVENTIONAL",[52],"NA","European clinical guidelines do not establish a clear recommendation neither for nor against omentectomy of this segment, the American clinical guidelines recommend omentectomy in view of its potential long-term oncological benefit, and Japanese clinical guidelines only recommend 2nd segment omentectomy in locally advanced gastric cancers (stage T3-T4) recommending omental preservation in early gastric cancers (stage T1-T2).\n\nFaced with this lack of consensus, we propose a randomized, prospective and multicentric study in patients with resectable gastric cancer in stage T3-4 N+\u002F- M0. Patients will be randomized into two groups, one where omentectomy of the 2nd omental portion will be performed and another where omental preservation will be performed.\n\nThe aim of our study is to analyze the disease-free interval and survival between both groups, also comparing postoperative complications and mortality.",[55],"Cancer of Stomach","NOT_YET_RECRUITING","2023-02-16",{"date":59,"type":60},"2023-02-28","ACTUAL",{"date":62,"type":49},"2024-01-01",{"date":64,"type":49},"2031-07-01",{"name":5,"class":6}]